Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab

Trial Details

NCT ID
NCT03803553
Phase
PHASE3
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • FOLFIRI Protocol
  • ACTIVE SURVEILLANCE
  • Nivolumab Protocol
  • Encorafenib/Binimetinib/Cetuximab Protocol
  • Trastuzumab + Pertuzumab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon. Any T \[Tx, T1, T2, T3, or T4-\], N1-2M0.
  • Participants must have completely resected disease. In patients with tumor adherent to adjacent structures, en block RO resection must be documented.
  • Entire tumor must be in the colon (rectal involvement is excluded).
  • Participants must have completed standard adjuvant chemotherapy per the discretion of the treating physician. Standard therapy includes FOLFOX, CAP…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →